Share on StockTwits

Relypsa (NASDAQ:RLYP) released its earnings data on Monday. The company reported ($0.51) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.57) by $0.06, Analyst Ratings Network.com reports.

On the ratings front, analysts at Wedbush raised their price target on shares of Relypsa from $56.00 to $57.00 in a research note on Tuesday, May 13th. They now have an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $48.17.

Shares of Relypsa (NASDAQ:RLYP) traded down 5.69% during mid-day trading on Monday, hitting $25.70. 421,199 shares of the company’s stock traded hands. Relypsa has a 52 week low of $11.55 and a 52 week high of $52.74. The stock’s 50-day moving average is $23.98 and its 200-day moving average is $28.62. The company’s market cap is $869.8 million.

Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.